Gene products or pathways that are aberrantly activated in cancer but not in normal tissue
hold great promises for being effective and safe anticancer therapeutic targets. Many …

High-throughput drug screening has facilitated the discovery of drug combinations in cancer.
Many existing studies adopted a full matrix design, aiming for the characterization of drug …

Rational design of drug combinations has become a promising strategy to tackle the drug
sensitivity and resistance problem in cancer treatment. To systematically evaluate the pre …

Combinatorial therapies have been recently proposed to improve the efficacy of anticancer
treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug …

Oncology drug combinations can improve therapeutic responses and increase treatment
options for patients. The number of possible combinations is vast and responses can be …

The majority of diseases are associated with alterations in multiple molecular pathways and
complex interactions at the cellular and organ levels. Single-target monotherapies therefore …

Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

A promising alternative to address the problem of acquired drug resistance is to rely on
combination therapies. Identification of the right combinations is often accomplished through …

Complex diseases like cancer are regulated by large, interconnected networks with many
pathways affecting cell proliferation, invasion, and drug resistance. However, current cancer …

Drug combinations have been proposed as a promising therapeutic strategy to overcome
drug resistance and improve efficacy of monotherapy regimens in cancer. This strategy aims …